Entelos is a pioneer in the field of predictive biosimulation in drug discovery and development. The company offers comprehensive biosimulation tools aimed at enhancing the efficiency of discovery and boosting clinical success rates. With over 15 years of experience, Entelos specializes in supporting R&D organizations in forecasting optimal pathways to success through the simulation of systems biology.
The company's offerings include mechanism-based mathematical models, virtual patients and populations, specialized biosimulation software, and expert biosimulation consulting. The company operates in the biotechnology, health care, and health and wellness industries, fueling innovation and advancement in these critical sectors.
Having been founded in 1996, Entelos has a well-established presence in the market. The company received a significant Post-IPO Equity investment on 21 June 2013, with Michaelson Capital Partners and Clearlake Capital Group as the investors, reaffirming its potential and attracting interest from prominent investment firms.
